Ra Capital Management, L.P. Ascendis Pharma A/S Transaction History
Ra Capital Management, L.P.
- $5.82 Billion
- Q3 2025
A detailed history of Ra Capital Management, L.P. transactions in Ascendis Pharma A/S stock. As of the latest transaction made, Ra Capital Management, L.P. holds 10,281,496 shares of ASND stock, worth $2.1 Billion. This represents 35.1% of its overall portfolio holdings.
Number of Shares
10,281,496
Previous 10,281,496
-0.0%
Holding current value
$2.1 Billion
Previous $1.77 Billion
15.19%
% of portfolio
35.1%
Previous 38.78%
Shares
20 transactions
Others Institutions Holding ASND
# of Institutions
318Shares Held
65MCall Options Held
476KPut Options Held
142K-
Westfield Capital Management CO LP Boston, MA5.26MShares$1.08 Billion4.77% of portfolio
-
Avoro Capital Advisors LLC New York, NY5.11MShares$1.04 Billion13.88% of portfolio
-
Janus Henderson Group PLC London, X04.32MShares$884 Million0.41% of portfolio
-
Lombard Odier Asset Management (Europe) LTD London, X04.27MShares$873 Million0.89% of portfolio
-
Artisan Partners Limited Partnership Milwaukee, WI3.72MShares$761 Million1.13% of portfolio
About Ascendis Pharma A/S
- Ticker ASND
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 55,810,200
- Market Cap $11.4B
- Description
- Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult h...